Transgenomic Inc announced that Katherine A. Richardson, PhD has joined the company as Technical Director for Laboratory Services. Dr Richardson will be responsible for managing the day-to-day operations of Transgenomic’s Laboratory Services labs, and will report to Craig Tuttle, Transgenomic’s president and chief executive officer.
Dr. Richardson has more than 25 years of genetic laboratory experience. She joins Transgenomic following eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Previously Dr Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis.
"Dr. Richardson has an impressive background and we are pleased to welcome her to Transgenomic," said Mr. Tuttle. "She clearly has the stature and expertise in the scientific community we are looking for as we further develop our laboratory services business as well as very strong ties to pharmaceutical research which should help us further expand our Pharmacogenomics services business. Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer. In particular, we look forward to tapping Dr. Richardson’s extensive experience in pharmaceutical drug development and companion diagnostic testing as well as in regulatory and laboratory operating procedures."
Dr. Richardson holds an SB degree in life sciences from the Massachusetts Institute of Technology and a PhD in molecular cellular developmental biology from Iowa State University.
Source: Transgenomic
